Pfizer bets big on immuno-oncology combos with Merck KGaA

By BC Staff | Nov 18, 2014 | 3:24 AM GMT

Pfizer Inc. (NYSE:PFE) is betting it can jump to frontrunner status with combination immunotherapies for cancer on the back of Monday's agreement to co-develop and co-commercialize its portfolio of immuno-oncology assets with Merck KGaA (Xetra:MRK).

Pfizer will pay $850 million up front, plus